当前位置: X-MOL 学术Nat. Rev. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Intralesional heterogeneity on PSMA PET–CT predicts mCRPC outcomes
Nature Reviews Urology ( IF 12.1 ) Pub Date : 2024-09-13 , DOI: 10.1038/s41585-024-00943-2
Maria Chiara Masone 1
Affiliation  

Intra-tumour heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) poses a challenge to treatment, owing to variability in tumour growth and response to therapy. Currently available tools such as response evaluation criteria in solid tumors (RECIST) and circulating tumour DNA (ctDNA) are useful methods to measure patient response to treatment but do not enable the assessment of individual tumour lesions with high resolution.

In a new study published in Med, the potential of 68Ga-prostate-specific membrane antigen (PSMA) + 18F-fluorodeoxyglucose (FDG) paired positron emission tomography–computed tomography (PET–CT) was assessed to capture intralesional response heterogeneity (ILRH) and improve risk stratification in patients with mCRPC.



中文翻译:


PSMA PET-CT 的病灶内异质性可预测 mCRPC 结局



由于肿瘤生长和对治疗反应的可变性,转移性去势抵抗性前列腺癌 (mCRPC) 患者的肿瘤内异质性对治疗构成挑战。目前可用的工具,如实体瘤反应评估标准 (RECIST) 和循环肿瘤 DNA (ctDNA),是衡量患者对治疗反应的有用方法,但不能以高分辨率评估单个肿瘤病变。


在发表在《医学》上的一项新研究中,评估了 68个 Ga-前列腺特异性膜抗原 (PSMA) + 18个 F-氟脱氧葡萄糖 (FDG) 配对正电子发射断层扫描-计算机断层扫描 (PET-CT) 的潜力,以捕获病灶内反应异质性 (ILRH) 并改善 mCRPC 患者的风险分层。

更新日期:2024-09-13
down
wechat
bug